Trial Profile
An observational, retrospective study evaluated the efficacy and safety of Eslicarbazepine acetate in patients with focal epilepsies in daily clinical practice in Galicia, Spain
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2016
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- Acronyms ESLI-ATLANTICO
- 04 Mar 2016 New trial record